Gawronski Kristen M
Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio.
J Pediatr Pharmacol Ther. 2015 Jan-Feb;20(1):61-5. doi: 10.5863/1551-6776-20.1.61.
There is limited information regarding the use of daptomycin in the neonatal population, and dosage adjustments for neonates with renal dysfunction. We report on the successful use of daptomycin in a 1-month-old, former 24-week gestation neonate with persistent methicillin-resistant Staphylococcus epidermidis (MRSE) bacteremia and impaired renal function. We also review the available literature supporting daptomycin use in the neonatal period. Daptomycin peak and trough serum levels were obtained immediately prior to and 60 minutes after the fifth dose. While vancomycin remains the drug of choice for methicillin-resistant Staphylococcal infections, due to increasing reports of treatment failures, alternative therapies are recommended. Based on mounting evidence, daptomycin may be considered an option in persistently bacteremic neonates who fail vancomycin therapy, although further investigation is warranted.
关于达托霉素在新生儿群体中的使用以及肾功能不全新生儿的剂量调整，相关信息有限。我们报告了达托霉素在一名1个月大、孕24周的前早产儿中的成功应用，该患儿患有持续性耐甲氧西林表皮葡萄球菌（MRSE）菌血症且肾功能受损。我们还回顾了支持在新生儿期使用达托霉素的现有文献。在第五剂给药前即刻和给药后60分钟测定了达托霉素的血清峰浓度和谷浓度。虽然万古霉素仍然是耐甲氧西林葡萄球菌感染的首选药物，但由于治疗失败的报道日益增多，推荐使用替代疗法。基于越来越多的证据，对于万古霉素治疗失败的持续性菌血症新生儿，可考虑将达托霉素作为一种选择，尽管仍需进一步研究。
